Navigation Links
YM BioSciences Closes Public Offering of Common Shares
Date:12/17/2010

r of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and an
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, the ... today announced the hiring of veteran equity analyst Charles ... analyst. Mr. Butler will focus on the biotech/biopharma sector. ... a wealth of experience and a broad network of ... Senior Managing Director and Head of Equities at Guggenheim ...
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
(Date:8/27/2014)... According to the 2013 Raw Material ... look and feel of markets for raw materials and ... will push for more branded, science-backed products.” , Natural ... market growth in the last decade as consumers increasingly ... cosmetics to fit a more ‘wellness’ lifestyle approach. ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... to develop bioelectronic technologies, today announced that it has ... U.S. Securities and Exchange Commission relating to a proposed ... of shares to be offered and the price range ... Jefferies LLC will act as the book-running ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... 28 Neurotech Pharmaceuticals, Inc. today announced that the ... biologic effect in two Phase 2 clinical trials for ... developing condition that causes the progressive degeneration of rod ... time diminishes night and peripheral vision and eventually leads ...
... SpyGlass(R) Direct Visualization System can now be used ... NATICK, Mass., May 28 Boston Scientific Corporation ... it has received 510(k) clearance from the U.S. ... SpyScope(R) Access and Delivery Catheter for diagnostic and ...
... presenting at the Global Crop Protection Summit and exposition on 15-17th ... ... London, UK (PRWeb UK) - Pira International and ... Protection Summit in Edinburgh, Scotland on 15 - 17 September 2009. ...
Cached Biology Technology:Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 2Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 3Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 5FDA Clears Boston Scientific's SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System 2FDA Clears Boston Scientific's SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System 3FDA Clears Boston Scientific's SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System 4Call for papers for Pira International's Global Crop Protection Summit 2009 2
(Date:8/27/2014)... of Utah biologist agan Sekercioglu, who campaigns to save ... highest science prize, which is similar to the U.S. ... researchers picked for 2014 the top awards by TUBITAK, ... researchers won the Science Award and two including ... to the Science Award but for scientists who are ...
(Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
Breaking Biology News(10 mins):University of Utah biologist wins Turkey's top science prize 2Potential therapy for incurable Charcot-Marie-Tooth disease 2
... development and software company, has secured an exclusive ... deal has potential to enhance various forms of ... Proteomics is the scientific next step in vital ... founded in 2006 in Cleveland near Case Western ...
... In one of the most comprehensive studies of its kind, ... with the Harvard School of Global Health have found that people ... ischemic heart disease and tend to live longer than others. ... Colorado mountains helps reduce the risk of dying from heart ...
... ORLANDO, Fla. The American Association for Cancer Research ... Education Award for Undergraduate Students at the AACR 102nd Annual ... The primary purpose of the AACR-Thomas J. Bardos Science Education ... the undergraduate level to enter the field of cancer research. ...
Cached Biology News:Case Western Reserve and NeoProteomics announce exclusive option 2Study shows living at high altitude reduces risk of dying from heart disease 2AACR awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students 2AACR awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students 3
... Sigmas FLAG Immunoprecipitation kit allows a ... of an active FLAG-tagged protein. The ... gel, which is a highly specific ... resin. The use of affinity resin ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... is a chromogenic medium for the ... Salmonella (except S. thyphi) and total ... detection takes a maximum of 24 ... no sterilization during preparation and performs ...
This modular benchtop laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Options include a work bench, ionizaing bar, and air velocity gauge....
Biology Products: